Safety and efficacy of biosimilars in oncology

MLA

Schellekens, Huub, et al. “Safety and Efficacy of Biosimilars in Oncology.” The Lancet Oncology, vol. 17, Nov. 2016, pp. e502–09. EBSCOhost, https://doi.org/10.1016/s1470-2045(16)30374-6.

APA

Schellekens, H., Smolen, J. S., Dicato, M., Rifkin, R. M., Sub Biotechnological drugs, & Pharmaceutics. (2016). Safety and efficacy of biosimilars in oncology. The Lancet Oncology, 17, e502–e509. https://doi.org/10.1016/s1470-2045(16)30374-6

Chicago

Schellekens, Huub, Josef S. Smolen, Mario Dicato, Robert M. Rifkin, Sub Biotechnological drugs, and Pharmaceutics. 2016. “Safety and Efficacy of Biosimilars in Oncology.” The Lancet Oncology 17 (November): e502–9. doi:10.1016/s1470-2045(16)30374-6.